Cargando…

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by chronic abdominal pain associated with changes in bowel habits. It is the most common GI problem seen by gastroenterologists. IBS is a heterogenous disorder encompassing a spectrum of underlying mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Rebecca, Staller, Kyle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153999/ https://www.ncbi.nlm.nih.gov/pubmed/32308371 http://dx.doi.org/10.2147/DDDT.S216056

Ejemplares similares

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea
por: Abel, Jessica L., et al.
Publicado: (2018)

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
por: Brenner, Darren M., et al.
Publicado: (2019)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity
por: Anwer, Md. Khalid, et al.
Publicado: (2023)

Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide
por: Brenner, Darren M, et al.
Publicado: (2021)

Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
por: Anwer, Md. K., et al.
Publicado: (2017)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
por: Chey, W. D., et al.
Publicado: (2017)

New Pathways, New Targets: Visceral Hypersensitivity Pathogenesis in Irritable Bowel Syndrome
por: Barshop, Kenneth, et al.
Publicado: (2016)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Therapy of the postinfectious irritable bowel syndrome: an update
por: IACOB, TEODORA, et al.
Publicado: (2017)

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
por: Mangel, Allen W, et al.
Publicado: (2012)

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
por: Chiba, Toshimi, et al.
Publicado: (2013)

An Asian perspective on irritable bowel syndrome
por: Jung, Kee Wook, et al.
Publicado: (2023)

Update in diagnosis and management of irritable bowel syndrome
por: Hung, Tsung-Hsing, et al.
Publicado: (2023)

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome
por: Zhan, Kai, et al.
Publicado: (2020)

Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions
por: Cangemi, David J., et al.
Publicado: (2019)

Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
por: Padhy, Susanta Kumar, et al.
Publicado: (2015)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
por: Colomier, Esther, et al.
Publicado: (2021)

Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial
por: Zheng, Hui, et al.
Publicado: (2016)

Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis
por: Guo, Jianbo, et al.
Publicado: (2020)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Evaluation of Eluxadoline Effect on Cardiac Repolarization
por: Bonifacio, Laura, et al.
Publicado: (2018)

Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome
por: Katsumata, Ryo, et al.
Publicado: (2017)

Depression and Structural Factors Are Associated With Symptoms in Patients of Irritable Bowel Syndrome With Diarrhea
por: Lu, Jia, et al.
Publicado: (2020)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome
por: Nee, Judy, et al.
Publicado: (2019)

Metabolomics analysis of herb-partitioned moxibustion treatment on rats with diarrhea-predominant irritable bowel syndrome
por: Lin, Xianwei, et al.
Publicado: (2019)

Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome
por: Liu, De-Rong, et al.
Publicado: (2018)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3gjih208o5jr7pa6fq9ijjdahn